Dupilumab, a fully human monoclonal antibody, added to existing inhaled corticosteroid therapy significantly reduced the yearly number of exacerbations in children with moderate-to-severe asthma, compared with inhaled corticosteroid (ICS) therapy alone.

This article is available free of charge.

Simply log in to access the full article, or register for free if you do not yet have a username and password.

Publication HistoryIdentification

DOI: https://doi.org/10.1016/S2213-2600(21)00260-5

Copyright

© 2021 Elsevier Ltd. All rights reserved.

ScienceDirectAccess this article on ScienceDirect